SCIENCE@home

Male rats treated with subchronic PCP show intact olfaction and enhanced interest for a social odour in the olfactory habituation/dishabituation test

Emilia Tarland,J. Brosda

Published 2018 in Behavioural Brain Research

ABSTRACT

HighlightsSubchronic PCP treatment did not interfere with olfactory function in male rats.Olfactory exploratory motivation was unaltered by subchronic PCP.Male rats treated with subchronic PCP spent more time investigating a novel social odour. ABSTRACT The olfactory system participates in many sensory processes, and olfactory endophenotypes appear in a variety of neurological disorders such as Alzheimer’s and Parkinson’s disease, depression and schizophrenia. Social withdrawal is a core negative symptom of schizophrenia and animal models have proven to be invaluable for studying the neurobiological mechanisms and cognitive processes behind the formation of social relationships. The subchronic phencyclidine (PCP) rat model is a validated model for negative symptoms of schizophrenia, such as impaired sociability. However, the complete range of social behaviour and deficits in the model are still not fully understood. Intact rodent olfaction is essential for a wide range of social behaviour and disrupted olfactory function could have severe effects on social communication and recognition. In order to examine the olfactory ability of male rats treated with subchronic PCP, we conducted an olfactory habituation/dishabituation test including both non‐social and social odours. The subchronic PCP‐treated rats successfully recognized and discriminated among the odours, indicative of intact olfaction. Interestingly, the subchronic PCP‐treated rats showed greater interest for a novel social odour compared to the saline‐treated rats and the rationale remains to be elucidated. Our data indicate that subchronic PCP treatment does not disrupt olfactory function in male rats. By ruling out impaired olfaction as cause for the poor social interaction performance in subchronic PCP‐treated rats, our data supports the use of NMDA receptor antagonists to model the negative symptoms of schizophrenia.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-50 of 50 references · Page 1 of 1

CITED BY

Showing 1-8 of 8 citing papers · Page 1 of 1